Radiation Dose-Volume Effects for Liver SBRT
Moyed Miften, Yevgeniy Vinogradskiy, Vitali Moiseenko, Jimm Grimm, Ellen Yorke, Andrew Jackson, Wolfgang A Tomé, Randall K Ten Haken, Nitin Ohri, Alejandra Méndez Romero, Karyn A Goodman, Lawrence B Marks, Brian Kavanagh, Laura A Dawson, Moyed Miften, Yevgeniy Vinogradskiy, Vitali Moiseenko, Jimm Grimm, Ellen Yorke, Andrew Jackson, Wolfgang A Tomé, Randall K Ten Haken, Nitin Ohri, Alejandra Méndez Romero, Karyn A Goodman, Lawrence B Marks, Brian Kavanagh, Laura A Dawson
Abstract
Stereotactic body radiation therapy (SBRT) has emerged as an effective, noninvasive treatment option for primary liver cancer and metastatic disease occurring in the liver. Although SBRT can be highly effective for establishing local control in hepatic malignancies, a tradeoff exists between tumor control and normal tissue complications. The objective of the present study was to review the normal tissue dose-volume effects for SBRT-induced liver and gastrointestinal toxicities and derive normal tissue complication probability models.
Conflict of interest statement
Conflict of interest: none.
Copyright © 2018 Elsevier Inc. All rights reserved.
Figures
References
- Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893–2917.
- Paley MR, Ros PR. Hepatic metastases. Radiol Clin North Am. 1998;36:349–363.
- Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery. 1994;116:703–711.
- Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946.
- Aloia TA, Vauthey J-N, Loyer EM, et al. Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg. 2006;141:460–467.
- Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: Update of the initial phase I/II trial. Front Radiat Ther Oncol. 2004;38:100–105.
- Wulf J, Hädinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177:645–655.
- Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62:1371–1378.
- Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–1578.
- Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486–493.
- Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–1591.
- Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–1639.
- Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26:657–664.
- Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e447–e453.
- Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol. 2006;45:831–837.
- Kavanagh BD, Miften M, Rabinovitch RA. Advances in treatment techniques: Stereotactic body radiation therapy and the spread of hypofractionation. Cancer J. 2011;17:177–181.
- McCammon R, Schefter TE, Gaspar LE, et al. Observation of a doseecontrol relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73:112–118.
- Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–821.
- Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76:S94–S100.
- Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: Dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78:1073–1080.
- Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118:5424–5431.
- Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84:355–361.
- Bae SH, Kim MS, Cho CK, et al. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic liver cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28:213–219.
- Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 2012;7:67.
- Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: Is there a dose response relationship? Int J Radiat Oncol Biol Phys. 2011;81:e39–e47.
- Barney BM, Markovic SN, Laack NN, et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT) Int J Radiat Oncol Biol Phys. 2013;87:73–80.
- Jabbour SK, Hashem SA, Bosch W, et al. Upper abdominal normal organ contouring guidelines and atlas: A radiation therapy oncology group consensus. Pract Radiat Oncol. 2014;4:82–89.
- Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739–8747.
- Velec M, Haddad CR, Craig T, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97:939–946.
- Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5:e443–e449.
- Toesca DAS, Osmundson EC, von Eyben R, et al. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Pract Radiat Oncol. 2017;7:173–182.
- Liang SX, Zhu XD, Xu ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65:426–434.
- Burman C, Kutcher GJ, Emami B, et al. Three-dimensional photon treatment planning report of the collaborative working group on the evaluation of treatment planning for external photon beam radio-therapy: Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135.
- Källman P, Ågren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62:249–262.
- Morgan BJ. Analysis of quantal response data. In: Smith RL, Tong H, Keiding N, et al., editors. Monographs on Statistics and Applied Probability. Boca Raton, FL: CRC Press; 1992. p. 46.
- Stinauer MA, Diot Q, Westerly DC, et al. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. Int J Radiat Oncol Biol Phys. 2012;83:e613–e618.
Source: PubMed